This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bonow, R. O. Articles by Epstein, S. E. Search for Related Content PubMed PubMed Citation Articles by Bonow, R. O. Articles by Epstein, S. E.

Circulation, Vol 64, 787-796, Copyright © 1981 by American Heart Association

ARTICLES

Effects of verapamil on left ventricular systolic function and diastolic filling in patients with hypertrophic cardiomyopathy

RO Bonow, DR Rosing, SL Bacharach, MV Green, KM Kent, LC Lipson, BJ Maron, MB Leon and SE Epstein

Verapamil improves exercise capacity in patients with hypertrophic cardiomyopathy (HCM), but its mechanism of action are unknown. We examined the effects of oral verapamil (320-480 mg/day) on resting left ventricular (LV) systolic and diastolic function in patients with HCM. High-temporal-resolution time-activity curves from gated technetium-99m radionuclide angiograms were analyzed before and after verapamil therapy in 40 patients, of whom 16 were also studied during propranolol therapy (80-960 mg/day). All but one patient had normal or supranormal systolic function, but 70% had evidence of diastolic dysfunction, defined as peak LV filling rate (PFR) less than 2.5 end-diastolic volumes (EDV)/sec or time to PFR greater than 80 msec. Verapamil did not change LV ejection fraction, peak ejection rate or ejection time, but did increase PFR (control 3.3 +/- 1.0 EDV/sec, verapamil 4.1 +/- 1.1 EDV/sec; p less than 0.001) and reduce time to PFR (control 187 +/- 56 msec, verapamil, 159 +/- 34 msec; p less than 0.001). Only 30% of patients had evidence of diastolic dysfunction during verapamil. In contrast, propranolol did not change LV ejection fraction, PFR or time to PFR, but did prolong ejection time and reduce peak ejection rate. Thus, LV diastolic filling is abnormal in a high percentage of patients with HCM, and verapamil normalizes or improves these abnormalities without altering systolic function. This mechanism may contribute to the clinical improvement of many HCM patients during verapamil therapy.

This article has been cited by other articles:

				M. A. Fifer and G. J. Vlahakes Management of Symptoms in Hypertrophic Cardiomyopathy Circulation, January 22, 2008; 117(3): 429 - 439. [Full Text] [PDF]

				S. Isobe, H. Izawa, Y. Takeichi, M. Nonokawa, M. Nanasato, A. Ando, K. Kato, M. Ikeda, T. Murohara, and M. Yokota Relationship Between Exercise-Induced Myocardial Ischemia and Reduced Left Ventricular Distensibility in Patients with Nonobstructive Hypertrophic Cardiomyopathy J. Nucl. Med., November 1, 2003; 44(11): 1717 - 1724. [Abstract] [Full Text] [PDF]

				B. J. Maron Hypertrophic Cardiomyopathy: A Systematic Review JAMA, March 13, 2002; 287(10): 1308 - 1320. [Abstract] [Full Text] [PDF]

				Y. Takeichi, M. Yokota, M. Iwase, H. Izawa, T. Nishizawa, R. Ishiki, F. Somura, K. Nagata, S. Isobe, and A. Noda Biphasic changes in left ventricular end-diastolic pressure during dynamic exercise in patients with nonobstructive hypertrophic cardiomyopathy J. Am. Coll. Cardiol., August 1, 2001; 38(2): 335 - 343. [Abstract] [Full Text] [PDF]

				K. Nakajima, J. Taki, M. Kawano, T. Higuchi, S. Sato, C. Nishijima, K. Takehara, and N. Tonami Diastolic Dysfunction in Patients with Systemic Sclerosis Detected by Gated Myocardial Perfusion SPECT: An Early Sign of Cardiac Involvement J. Nucl. Med., February 1, 2001; 42(2): 183 - 188. [Abstract] [Full Text]

				P. Spirito, C. E. Seidman, W. J. McKenna, and B. J. Maron The Management of Hypertrophic Cardiomyopathy N. Engl. J. Med., March 13, 1997; 336(11): 775 - 785. [Full Text] [PDF]

				P. H. Pak, W. L. Maughan, K. L. Baughman, and D. A. Kass Marked Discordance Between Dynamic and Passive Diastolic Pressure-Volume Relations in Idiopathic Hypertrophic Cardiomyopathy Circulation, July 1, 1996; 94(1): 52 - 60. [Abstract] [Full Text]

				R. O. Cannon, A. A. Quyyumi, R. Mincemoyer, A. M. Stine, R. H. Gracely, W. B. Smith, M. F. Geraci, B. C. Black, T. W. Uhde, M. A. Waclawiw, et al. Imipramine in Patients with Chest Pain Despite Normal Coronary Angiograms N. Engl. J. Med., May 19, 1994; 330(20): 1411 - 1417. [Abstract] [Full Text]

				O. Lund and F. T. Jensen Late Cardiac Deaths After Isolated Valve Replacement for Aortic Stenosis. Relation to Impaired Left Ventricular Diastolic Performance Angiology, March 1, 1989; 40(3): 199 - 208. [Abstract] [PDF]